Media Articles Related to Raptiva (Efalizumab)
FDA Panel Backs Approval of Psoriasis Drug Brodalumab
Source: Medscape Allergy & Clinical Immunology Headlines [2016.07.20]
The panelists said that patients should be given proper informed consent about the risk for suicide.
Medscape Medical News
FDA Panel Backs Psoriasis Drug With Caveats
Source: MedPage Today Dermatology [2016.07.20]
(MedPage Today) -- Says suicide risk means brodalumab needs careful management
Valeant Psoriasis Drug's Suicide Risk Hard to Assess -FDA Staff
Source: Medscape Dermatology Headlines [2016.07.18]
Valeant Pharmaceuticals International Inc's experimental drug to treat psoriasis carries a potential risk of suicide that is challenging to assess due to limited data, a preliminary review by the U.S. Food and Drug Administration said on Friday.
Reuters Health Information
Suicide Risk Jeopardizes Promising New Psoriasis Drug
Source: MedPage Today Dermatology [2016.07.16]
(MedPage Today) -- Six completed suicides among brodalumab trial participants
Psoriasis Rashes, Symptoms, Treatments
Source: MedicineNet Psoriasis Specialty [2016.07.15]
Title: Psoriasis Rashes, Symptoms, Treatments
Created: 8/17/2012 12:00:00 AM
Last Editorial Review: 7/15/2016 12:00:00 AM
Published Studies Related to Raptiva (Efalizumab)
A short cycle of narrow-band UVB phototherapy in the early phase of long-term efalizumab can provide a quicker remission of moderate and severe psoriasis: a pilot study. 
CONCLUSION: This pilot study indicates that the combination with NB-UVB improves the efficacy of efalizumab monotherapy in the treatment of moderate to severe psoriasis. Copyright 2009 S. Karger AG, Basel.
Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. [2008.11]
Efalizumab is a humanized monoclonal CD11a antibody approved for treatment of psoriasis. Its immunomodulatory effects led us study how immune responses are modified and the possible consequences for vaccinations in clinical practice... These results expand our knowledge of how immune responses are modulated in humans by CD11a blockade and have implications for vaccinations of patients treated with this agent.
Long-term efficacy of up to 15 months' efalizumab therapy in patients with moderate-to-severe chronic plaque psoriasis. [2008.11]
The efficacy and safety of efalizumab in the treatment of moderate-to-severe chronic psoriasis has been established in studies of up to 3 years' duration. This study aims to describe the efficacy of up to 15 months' treatment with efalizumab and the convenience of therapy in patients with moderate-to-severe chronic plaque psoriasis.
Subcutaneous efalizumab is not effective in the treatment of alopecia areata. [2008.03]
BACKGROUND: Alopecia areata (AA) is a T-cell-mediated autoimmune disease. Efalizumab is a T-cell-targeted therapy approved for the treatment of psoriasis. OBJECTIVE: To assess the efficacy and safety of efalizumab in the treatment of moderate-to-severe AA... CONCLUSION: A 3- to 6-month trial of efalizumab was not effective in promoting hair regrowth in this small cohort of patients with moderate-to-severe AA.
Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis: An Open-Label Extension of a Phase IIIb Trial. 
BACKGROUND: Psoriasis is a chronic autoimmune disease characterized by infiltration of the dermis and epidermis by activated T cells and the hyperproliferation and abnormal differentiation of keratinocytes. It is a life-long disease with alternating periods of remission and recurrence. Efalizumab is a humanized, recombinant, T-cell targeting monoclonal antibody, approved for use in adults with chronic moderate to severe plaque psoriasis. OBJECTIVE: To assess the safety of continued or newly initiated treatment with efalizumab for up to 48 weeks in patients with psoriasis who were treated previously with efalizumab or placebo... CONCLUSIONS: These results support the short-term safety profile demonstrated for efalizumab over a longer-term therapy period of up to 60 weeks.
Clinical Trials Related to Raptiva (Efalizumab)
Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes [Completed]
The primary objective of this protocol is to test the safety and efficacy of a treatment
regimen consisting of maintenance therapy with efalizumab and sirolimus for 1 year followed
by withdrawal of efalizumab and maintenance therapy with sirolimus, for the prevention of
the destruction and rejection of islet transplants in type 1 diabetic recipients.
Genentech, the manufacturer of efalizumab voluntarily withdrew the drug from the U. S. market
in April of 2009. Previously transplanted subjects have been transitioned to alternative
immunosuppressives and no new subjects will be transplanted under this protocol.
Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids [Completed]
RATIONALE: Efalizumab may be an effective treatment for graft-versus-host disease of the
skin caused by a donor stem cell transplant.
PURPOSE: This clinical trial is studying the side effects and how well efalizumab works in
treating patients with graft-versus-host disease of the skin that did not respond to
Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab [Withdrawn]
In this single-center therapeutic study, we will study the ability of efalizumab to protect
remaining beta cells in teenagers and young adults who have been newly diagnosed with type 1
diabetes mellitus. Efalizumab is a monoclonal antibody which prevents the activation of
antigen specific T lymphocytes to sites of inflammation. Efalizumab was approved by the FDA
in 2003 for the treatment of psoriasis. It has been proven to be safe, well tolerated and
effective in targeting T cell mediated disorders like those seen in autoimmunity.
Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy [Completed]
To evaluate whether a short-term course of methotrexate in patients treated with efalizumab
(Raptiva) increases efficacy. The secondary objectives of this study are 1) to evaluate the
efficacy of Raptiva in maintaining the clinical improvement induced by short-term treatment
with combination therapy of Raptiva and methotrexate 2) to evaluate the safety of short-term
combination therapy of Raptiva and methotrexate.
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp [Completed]
This was a Phase IV randomized, double-blind, placebo-controlled study designed to evaluate
the safety and efficacy of subcutaneous efalizumab in adult patients (18 years of age and
older) with chronic moderate to severe plaque psoriasis with involvement of the scalp who
had no previous exposure to efalizumab. The study consisted of a screening period, a
double-blind treatment period, an open-label treatment period, and an observation/follow-up
period. The study enrolled 100 patients. 11 patients were excluded from all analyses
because of data issues.
Reports of Suspected Raptiva (Efalizumab) Side Effects
Squamous Cell Carcinoma (2),
Lymphocyte Count Increased (1),
Skin Discolouration (1),
Upper Respiratory Tract Infection (1),
Oedema Peripheral (1),
Hearing Impaired (1),
Acute Myocardial Infarction (1), more >>